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Background: Nocardiosis is a localized or disseminated infection caused by an aerobic actinomycete that usually 
affects immunocompromised patients. Nocardiosis has been described in patients receiving immunosuppressive 
therapy, organ transplant recipients, subjects with chronic pulmonary diseases, and patients infected with the human 
immunodeficiency virus (HIV). 
Data review: Nocardial infection shows a broad and variable geographic distribution. The clinical forms include 
pulmonary involvement, skin or soft tissue infection, and disseminated forms with brain and pulmonary lesions. 
Primary nocardial infection includes pulmonary or cutaneous and/or subcutaneous lesions. Disseminated disease is 
defined by the identification of nocardial infection in two or more organs. The lung is the most commonly involved 
organ, followed by the skin and the brain. HIV-related nocardiosis usually appears in patients with advanced 
immunodepression and CD4 counts less than 50 cells/ml. Sulfonamides are the standard therapy for nocardiosis 
and are effective in the majority of cases. Several other drugs, such as imipenem, amikacin, minocycline, amoxicillin 
clavulanic acid and third-generation cephalosporins, have also been used in these patients. Surgery is usually reserved 
for the drainage of abscesses. 
Conclusions: Nocardiosis is an important cause of opportunistic infection in immunosuppressed patients. Early 
recognition and prompt treatment usually results in complete cure, except for patients with nocardial brain abscesses, 
in whom the mortality remains at approximately 50%. 
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Infections caused by Nocardia species are infrequent 
but challenging to clinicians. They cause a wide variety 
of diseases in both normal and immunocompromised 
patients. In recent years, the number of case reports 
has been increasing, and this can be attributed to the 
improvements in diagnostic capabilities and the higher 
clinical index of suspicion accompanying the increased 
prevalence of immunosuppressed patients. The treat- 
ment of nocardiosis also requires expertise. This report 
reviews the epidemiology, physiopathology, clinical 
manifestations, diagnosis and treatment of this aerobic 
bacterial disease. 
INTRODUCTION 
Nocavdia is a genus of aerobic Actinomycetes respon- 
sible for localized or disseminated infections in animals 
and humans. The genus is named after Edward Nocard, 
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who in 1888 described the isolation of an aerobic 
Actinomycete from cattle with bovine farcy. Eppinger 
reported the first human case of nocardiosis in 1890.The 
incidence of human disease has increased substantially 
in the last two decades in association with an increasing 
population of immunocompromised hosts and improved 
methods for detection and identification of Nocardia 
spp. in the clinical laboratory. Hematogenous dissemi- 
nation from the lung can contribute to the development 
of subcutaneous or cerebral abscesses. In humans, infect- 
ion can also take place by penetration through the skin. 
The agents of these infections are aerobic fila- 
mentous Gram-positive, weakly acid-fast bacteria that 
live as soil saprophytes. The species that can infect 
humans are Nocardia asteroides and N. brasiliensis. 
The first of these, in most cases, shows pulmonary and 
systemic involvement; the second one is associated with 
cutaneous lesions and 1ymphadenitis.l 
The incidence in patients with acquired immuno- 
deficiency syndrome (AIDS) is between 0.1% and 0.3 %. 
These infections affect patients in advanced stages 
of HIV disease and with CD4’ T-cell counts below 
50 cell/yL.2 
EPIDEMIOLOGY 
Nocardiosis has a universal distribution, and affects 
people between 20 and 60 years of age. Cross and 
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Bindford noticed the high frequency with which 
nocardiosis complicates other pathologic conditions 
that act as predisposing causes, such as lymphoprolifer- 
ative syndromes, solid neoplasias, AIDS, liver cirrhosis, 
organ transplant and immunodepression treatments 
such as cytotoxics and corticosteroids.3 
There is a tendency to think that Nocardia infection 
affects only immunocompromised patients, but this is 
only partially true. In 1980, Curry4 reviewed 455 cases of 
nocardiosis; 39% of them did not receive immuno- 
suppressive therapy. Dominguez and Anthony5 found 
that 58% of cases of Nocardia infection occurred in 
immunocompetent hosts. Finally, Menendez et al6 
reported 10 cases with pulmonary nocardiosis; four of 
them were receiving corticosteroids, and two had 
concomitant HIV-l infection. Intravenous drug abuse 
also seems to be a risk factor. Palacios et al7 found an 
incidence of 82% in intravenous drug abusers. The use 
of systemic corticosteroids remains an important 
independent risk factor for nocardial infections. 
Recently, episodes of nocardiosis in AIDS patients 
and in recipients of solid organ and bone marrow 
transplants have been reported.8-12 Risk factors for the 
development of nocardiosis in these patients include 
early rejection of graft and intensive immunosuppressive 
therapy.13 Finally, there is a third group of illnesses that 
increase the risk for the development of nocardiosis; 
these are the chronic granulomatous diseases and hema- 
tologic malignancies. In these cases, the species that is 
found most frequently is N. @~inica.r~J~ 
The incidence of nocardiosis in AIDS patients 
shows geographic variations; it occurs mainly in rural 
regions rather than in urban areas. In general, AIDS 
patients with CD4’ T-cell counts less than 100 cell/yL 
are more likely to develop pulmonary and extra- 
pulmonary disease. The frequency of Nocavdia infections 
in HIV-l patients increased from 0.3% in 1985 to 1.8% 
in 1989. This incidence is still low, and one of the reasons 
for this, although not the only one, may be the extensive 
use of cotrimoxazole for Pneumocystis carinii pneu- 
monia prophylaxis. The clinical presentation requires a 
differential diagnosis with other pulmonary diseases 
such as tuberculosis.r6 
ETIOLOGY 
The Nocardia genus includes a variety of species that 
are important pathogens in humans. N. asteroides 
complex includes a heterogeneous group of 
microorganisms with similar biochemistry, structure 
and antimicrobial resistance. This complex includes the 
subgroup N. asteroides sensu stricto, N. farcinica and N. 
nova. With regard to resistance, N. farcinica is resistant 
to tobramycin and third-generation cephalosporins. N. 
brasiliensis is resistant to minocycline and produces 
lymphocutaneous disease (sporotrichoid form), 
whereas N. transvalensis and N. otitidiscaviarum cause 
mostly noncutaneous disease. 
PATHOGENESIS 
Although the exact mechanism is unknown, the main 
route of acquisition of pulmonary nocardiosis is pro- 
bably through direct inhalation of contaminated particles. 
Most of the cases start as minor respiratory syndromes 
that self-limit spontaneously. In some patients, the in- 
fection spreads, starting from the lung, with a particular 
predilection for the brain, skin and subcutaneous tissues. 
Infection with Nocardia may also occur by direct 
inoculation through the skin, producing cellulitis, 
lymphangitis or both. 
Intravenous drug abuse may provide another route 
of entry, i.e. direct inoculation through the skin, leading 
to abscesses, especially in recent venopuncture sites.r7Jg 
Surgical wound infections due to N. furcinica have also 
been described.r9 Rarely, gastrointestinal colonization 
has been reported, resulting from inhalation of spores or 
sputum swallowing. There is no definitive evidence of 
person-to-person transmission of Nocardia infections. 
Host resistance to nocardial infection depends 
on sufficient numbers, and the phagocytic and lytic 
capabilities, of polymorphonuclear cells, and cell- 
mediated immunity. The last of these fails in AIDS 
patients and predisposes to the development of severe 
forms of the disease. However, the low frequency of this 
complication in patients with advanced HIV-l disease 
can be attributed to sulfonamide therapy and the leading 
role of neutrophils in the immune response to Nocardia. 
CLINICAL MANIFESTATIONS 
Pulmonary nocardiosis 
This is an acute, subacute or chronic suppurative 
infection with a pronounced tendency for remissions 
and exacerbations. The clinical manifestations are acute 
or subacute pneumonia with abscess or cavity formation 
(Figure 1). Generally, the initial diagnoses are pneu- 
monia, tuberculosis, and carcinoma or lung abscesses 
Figure 1. Chest radiograph showing acute pneumonia with 
abscess and cavity, due to N. asteroides. 
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of other etiologies. The most common symptoms are 
productive cough, high fever, chills, sweats and weight 
10~s.~~ Twenty-five percent of cases present with pleural 
involvement, including pleural effusions and empyema. 
Nothing in the radiographic presentation is sufficiently 
distinctive to allow a diagnosis. The chest X-ray may show 
fluffy infiltrates, upper-lobe processes with cavitation 
(mimicking pulmonary tuberculosis), lobar consolidation, 
irregular nodules or masses, often cavitated, or single 
and multiple abscesses, and even simple alveolar or 
interstitial reticular or reticulonodular infiltrates.20 
Also, miliary lesions and hiliar adenopathy have been 
described, as has presentation as an adult respiratory 
distress syndrome. 21 Rarely, Nocardia species can invade 
preexisting lung cavities, producing a ‘fungus ball’ 
appearance. Computed tomography (CT) reveals the 
presence of nodules or masses in more than 80% of 
patients. 
Pulmonary lesions show tissue necrosis with poly- 
morphonuclear leukocyte, macrophage and lymphocyte 
infiltrates, but usually not the hallmark epithelioid cells 
seen in tuberculosis. Sometimes, tissue sections may 
reveal a granulomatous response with central necrosis 
that may mimic tuberculosis or histoplasmosis. Pro- 
gressive fibrosis occurs in inadequately treated patients, 
with a chronic course similar to that of tuberculosis. 
Immunocompromised patients, including AIDS patients, 
with nocardial pulmonary involvement can be difficult 
to diagnose because of the possible coexistence of other 
opportunistic pathogens. 
Cutaneous and subcutaneous nocardiosis 
Primary cutaneous and subcutaneous nocardiosis 
represent 25% of cases, and can follow any puncture or 
other traumatic introduction of Nocardia with other 
microorganisms. Generally, this form is underdiagnosed, 
because culture incubation is not routinely done.22,23 In 
addition to the classic mycetoma, cutaneous infection 
also leads to cellulitis (Figures 2 and 3), pustules, 
pyoderma, paronychia, or localized abscesses that mimic 
infections due to pyogenic bacteria. It can also produce 
lymphangitis with subcutaneous nodules mimicking 
sporotrichosis, and for this reason is called the 
sporotrichoid form.24 
While any pathogenic Nocardia species may cause 
primary cutaneous or subcutaneous lesions, N brasiliensis 
is the most frequently isolated in cases of disseminated 
disease. Palasi et a125 described a retromammary abscess 
caused by N asteroides in an HIV-positive patient. 
Rarely, Nocardia species can be inoculated into the 
bloodstream in intravenous drug abusers, producing 
septic thrombophlebitis.20 
Mycetoma is a chronic cutaneous and subcutaneous 
disease that evolves progressively and causes a destructive 
infection of the skin, subcutaneous tissues, fascia, 
muscles and bones following local trauma to the hand, 
foot, leg or arm.24,26,27 It produces an area of localized 
swelling containing suppurative granulomas and multiple 
sinus tracts with macroscopic white-yellow granules. 
Mycetoma is the only clinical form of nocardiosis 
associated with the presence of such granules.27 At least 
half of the cases of mycetoma are caused by Nocardia 
species, whereas members of the genus Actinomadura 
are frequently recorded only in certain geographic areas. 
Systemic nocardiosis 
Primary nocardial infection, either respiratory or 
cutaneous, may spread hematogenously and lead to an 
extrapulmonary form of this disease. The presence of 
lesions in two or more organs of the body defines 
systemic or disseminated disease. The most common 
sites for dissemination include the central nervous 
system (CNS), skin and subcutaneous tissues, kidneys, 
joints, bones, heart and eyes.20,22,28 
In the early stages of systemic infection, Nocardia 
species behave as pyogenic bacteria, whereas the host 
cell response is dominated by neutrophils.24 Subse- 
Figure 2. Subcutaneous nocardiosis due to N. brasiliensis in an 
intravenous drug abuser, HIV seropositive. 
Figure 3. The same patient as in Figure 2 after antibiotic 
treatment. 
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quently, the illness evolves into a chronic phase, with 
macrophage and lymphocyte responses. Tissue abscesses 
result from the progressive tissue invasion with 
nocardial filaments. Generally, pulmonary and dissemi- 
nated forms progress unless treatment is started. That is 
to say, the infection is not self-limited, although it may 
evolve slowly over a period of many months or even 
years.29,30 Less frequent clinical presentations include 
peritonitis, epididymo-orchitis, iliopsoas and perirectal 
abscesses, pericarditis, endocarditis, septic arthritis, 
osteomyelitis and peritonitis in cases of chronic 
peritoneal dialysis. 24 Ramanathan and Rahirni31 reported 
a case of Nocardia pericarditis with pericardial 
effusion as an initial manifestation of HIV-l infection; 
N. asteroides was isolated from pericardial fluid. River0 
et a132 described a case of cardiac tamponade caused by 
N. asteroides in an HIV-infected patient. 
Eye involvement includes retinitis and endoph- 
thalmitis, but also surface lesions, as keratoconjunctivitis 
has been described as a consequence of traumatic 
inoculation.22 
In AIDS patients, the incidence of nocardiosis has 
increased since 1990.24 Beaman and Beaman reviewed 
71 cases of nocardiosis in AIDS patients from 1984 to 
1992. The most common sites of disease were the lung 
(51.3%) and the brain (11.7%). 
Central nervous system infection 
CNS infection occurs in more than 40% of cases of 
systemic nocardiosis. 24,30 More than 25% of reported 
cases, other than mycetomas, affected the CNS, and, in 
half of them, this was the only parenchyma involved.‘3”5 
The clinical manifestations are insidious, and, for this 
reason, diagnosis is difficult.13,24 The clinical symptoms 
result from the mass effect of brain abscesses and, less 
frequently, abscesses of the spinal cord and meninges.13 
CNS infection is generally diagnosed after the develop- 
ment of focal neurologic deficits and diagnostic 
aspiration of CNS lesions. There are reports of patients 
undergoing surgical excision for a presumed brain 
tumor whose postoperative cultures grew Nocardia. 
Sometimes, psychiatric disorders herald the 
infection.24x29,30 Patients with minimal neurologic 
symptoms can be treated with antibiotics only; however, 
in most cases, surgical excision is needed because of the 
natural tendency of nocardial abscesses to be multi- 
loculated. The abscesses can involve parietal, frontal or 
occipital cortex, basal ganglia and cerebellum. The 
majority of reported cases of Nocardia brain abscesses 
involve N. astevoides, although other species have been 
reported. 
Mamelak et a13’j reported 11 cases of nocardial 
abscesses treated between 1971 and 1993, and reviewed 
120 cases reported since 1950. The clinical findings 
included focal deficits in 42%, nonfocal findings in 27 %, 
and seizures in 30%. In this report, the abscesses were 
single in 54% and multiple in 38%; 34% of 131 patients 
were immunocompromised, and 15% of them had HIV- 
1 infection. In 66% of the cases, the authors verified 
extraneural localization, pulmonary in 38% and 
cutaneous and subcutaneous in 20%. The mortality rate 
was 33% in patients with single abscesses and 66% in 
those with multiple abscesses. In 22% of the cases, 
diagnosis was made by autopsy. Although the mortality 
rate for nocardial abscesses has dropped by almost 50% 
since the advent of CT, this percentage has not changed 
in immunocompromised patients, and is three times 
higher than for other bacterial brain abscesses (30% 
versus 10%). For this reason, stereotactic biopsy is 
needed for the isolation of the microorganisms. Finally, 
CNS infection can manifest with extrapyramidalism or 
acute meningoencephalitis.24 
Needle aspiration or biopsy may not be necessary to 
confirm the diagnosis for most patients with pulmonary 
nocardiosis; nevertheless, in AIDS patients, the 
possibility of infections with multiple organisms, or 
infection plus tumor (especially lymphomas), means that 
the diagnostic procedure must be modified. Beaman and 
Beaman noted that CNS infections tended to be 
destructive and more rapidly progressive in immuno- 
compromised hosts than in patients with normal host 
defenses, whose infections are insidious and slowly 
progressive. 
DIAGNOSIS 
The most common specimens from which Nocardia 
species are isolated are respiratory secretions, skin 
biopsies, aspiration from deep collections, cerebrospinal 
fluid (CSF) and biopsy smears. Gram staining and 
modified Kinyoun staining are the techniques for the 
identification of Nocardia. Direct smears typically show 
Gram-positive, beaded, branching filaments that are 
usually acid fast (Figure 4). In general, the colonies have 
a chalky white or cotton ball appearance because of the 
presence of abundant aerial filaments. 
Figure 4. Micrograph of a sputum smear stained with modified 
Kinyoun stain, showing the characteristic structure of Nocardia 
species. 
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Nocardia species will grow on most non-selective 
media used routinely for the culture of bacteria, fungi 
and mycobacteria. However, in specimens containing 
mixed flora, nocardial colonies are easily obscured by 
those of more rapidly growing bacteria, and the yield 
is increased by the use of selective media such as 
Thayer-Martin agar with antibiotics. Growth of 
Nocardia species may take from 48 h to several weeks, 
but typical colonies are usually seen after 3-5 days.37 
Once the microorganism is isolated, multiple laboratory 
tests can be used to differentiate the different species, 
especially from mycobacteria that can present a similar 
structural pattern. Exceptionally, Nocardia can be 
isolated from blood. 
When brain infection is present, the CSF shows 
protein elevation, hypoglycorrachia and neutrophilic 
pleocytosis. N. asteroides can be isolated rarely from 
CSE3* 
HISTOPATHOLOGIC DIAGNOSIS 
The lesions of nocardiosis cause intense suppuration, 
and the macroscopic aspects are similar to those of 
lesions caused by pyogenic bacteria. Different kinds of 
abscess can be seen, miliary or large and multiloculated. 
The absence of fibrosis, the small number of fistula and 
the lack of granules can differentiate these lesions from 
those of actinomycosis. There is not much of a tendency 
for the process to be limited.The histopathology of brain 
biopsy shows the existence of suppurative granuloma 
with central necrosis and fibrosis. 
TREATMENT 
Antibiotic treatment 
Clinical experience has shown that successful therapy 
requires the use of antimicrobial drugs in combination 
with appropriate surgical drainage. The optimal anti- 
microbial therapy depends on the severity and localiza- 
tion of the infection, the species of Nocardia, host 
immune status, potential drug interactions and toxicity 
associated with antibiotic use. In some circumstances, 
and especially in cases of relapse after therapy, 
antimicrobial susceptibility testing is recommended, 
and it is appropriate for a reference laboratory to 
confirm test results. Indications for testing include 
isolation of Nocardia species from areas of deep-seated 
or disseminated infection, lack of response to initial 
therapy, contraindications to the use of sulfonamides, 
and infections that are caused by resistant strains such 
as N. farcinica and N. otitidiscaviarum.33,3g42 On the other 
hand, a recent study showed an unexplained discrepancy 
with respect to the susceptibility of N. asteroides to 
sulfonamides between European patients and US 
patients. 41,42 Although different kinds of antibiotics 
have been shown to be active against Nocardia strains, 
sulfonamides have represented the treatment of choice 
since their introduction in the 1940s. They are active 
against N. brasiliensis, N. asteroides complex and N. 
transvaZensis,13,43~44 but are less effective in vitro against 
N. otitidiscaviarum.41,42 Some authors suggest the utility 
of the combination of trimethoprim (TMP) and 
sulfamethoxazole (SMX), based on their efficacy in this 
combination in comparison to sulfadiazine, in spite of 
the increased myelotoxicity, especially in patients 
receiving myelosuppressive therapy.43 
Pleuropulmonary infections caused by strains of N. 
asteroides complex respond favorably to sulfonamides in 
90% of cases.13 In adults with normal renal function and 
localized disease, the recommended dose of TMP is 
5-10 mg/kg per day, and that of SMX is 25 mglkg per 
day, divided into three or four doses. In patients with 
primary cutaneous infection including sporotrichoid 
nocardiosis, TMP-SMX at 5 mg/kg per day (TMP 
component) is sufficient in combination with surgical 
debridement. 
Higher initial doses (15 mg/kg TMP and 75 mg/kg 
SMX intravenously) are frequently used in patients with 
cerebral abscesses, extensive and disseminated infection, 
or AIDS.44-46 After 3-6 weeks, doses can be reduced 
and given orally. In severely ill or immunosuppressed 
patients, two or more drugs in combination can be 
necessary, including sulfonamides. Sulfadiazine and 
sulfisoxazole show equal efficacy in the treatment of 
nocardiosis. The recommended dose of sulfadiazine is 
lo-12 g/day and that of sulfisoxazole is 6-12 g/day, in 
four to six oral doses with a high fluid intake and oral 
sodium bicarbonate, because it can induce oliguria, 
azotemia and crystalluria. I3 Lower doses can be used in 
cases of pulmonary involvement.35 In AIDS patients, 
higher doses are needed. 47 In cases of disseminated 
forms and CNS involvement, the minimal course of 
treatment is 6 weeks, although the optimal duration may 
be up to 3 months. 48 Alternative antimicrobial agents 
should be considered in patients with allergy, gastro- 
intestinal intolerance or myelotoxicity. In these cases, 
amikacin is probably the most active agent in vitro 
against Nocardia species, except for N. transvalensis. l3 
Amikacin shows synergistic activity when used with 
other antimicrobials, especially imipenem, third-genera- 
tion cephalosporins and TMP-SMX. The major dis- 
advantages of amikacin are the necessity for parenteral 
administration and the potential for renal toxicity and 
ototoxicity with prolonged administration. 
Imipenem is also very active in vitro, although 
N. furcinica and N. brasiliensis are highly resistant to it.13 
Imipenem is most active when used with amikacin. This 
combination is the optimal parenteral therapy for initial 
treatment. Meropenem is an alternative to imipenem 
in patients with cerebral nocardiosis, because it has a 
similar pharmacokinetic profile, good CSF penetration 
and a lower incidence of seizures.49 
Minocycline may be effective (only N. transvalensis 
shows resistance) when it is used alone or in combination 
with other drugs or in sequential therapy.4,45 The usual 
doses are between 100 and 600 mg/day.50 
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Amoxicillin-clavulanate has been shown to be 
effective against N. asteroides, N. farcinica and N. 
brasiliensis, and may be especially useful in the treat- 
ment of cutaneous infections, especially those caused by 
B-lactamase-producing strains.51%52 
Third-generation cephalosporins are active against 
Nocardia species, with the exception of N. farcinica, 
N. transvalensis and N. otitidiscaviarum. Ceftriaxone, 
cefotaxime and cefuroxime are useful, especially in cases 
of cerebral nocardiosis, because they have excellent CSF 
penetration and low toxicity. 
Linezolid, a member of a new class of antibiotics 
called the oxazolidinones, has been shown to have in 
vitro activity against 56 strains of Nocardia species, 
including N. farcinica and N. transvalensis.53 
Surgical treatment 
The place of surgery in the management of nocardiosis 
depends on the site and extent of the infection. In 
extraneural disease, indications for aspiration, drainage 
or excision of abscesses are similar to those for other 
chronic bacterial infections. Therapeutic aspiration is 
generally inadequate in patients with thick-walled 
multiloculated abscesses, which contain free-flowing 
pus, including patients with mycetomas.36 In patients 
with brain abscesses, surgery should be performed when 
the abscesses are accessible and relatively large, the 
patient’s condition deteriorates or lesions progress 
within 2 weeks of therapy, or no reduction in abscess size 
is seen within a month of therapy.36 Decompression of 
lesions can be accomplished by stereotactic aspiration, 
although cure in many cases is achieved only after 
craniotomy and total excision.36%54 Mamelak et a13(j 
reported a significant reduction in mortality rate in 
patients with craniotomy (24%) in comparison to those 
who had undergone aspiration or drainage (50%). On 
the assumption that Nocardia brain abscesses are often 
multiple, surgery is extended, and the mortality rate is 
66%, compared to 33% for those with single abscesses. 
In contrast, in cases of bacterial abscesses, the mortality 
rate is less than 10%.55,56 
The mortality rate for nocardial brain abscesses 
has dropped by almost 50% since the introduction of 
CT. However, the reduction of the global mortality 
rate between 1975 and 1990 was not significant (39% 
versus 31%). In this same period, mortality rates were 
significantly higher among immunocompromised 
patients.36 
DURATION OF THERAPY AND PROGNOSIS 
Clinical improvement is evident within 7-10 days after 
the initiation of therapy. Parenteral therapy can be 
changed to an oral regimen, and high doses of TMP- 
SMX may be reduced after 3-6 weeks. Patients with 
extensive nocardiosis, subjects with lesions not accessible 
to surgery or those who respond slowly may benefit 
from prolongation of parenteral and oral treatment. 
Lack of response to initial therapy may be due to primary 
drug resistance, inadequate penetration of drugs into 
sites of infection, especially in abscesses, and immuno- 
compromised status, including AIDS.13 
The duration of therapy is variable, and depends on 
the localization of the lesions and the immune status. 
Cutaneous forms are cured after l-3 months of treat- 
ment; but prolonged therapy is required in cases of 
mycetoma.35,43 Pulmonary and systemic nocardiosis, 
excluding CNS involvement, should be treated for at 
least 6 months. In non-HIV-infected54 immunocom- 
promised patients, therapy should be continued for 12 
months or longer; depending on concurrent increases 
in immunosuppression, treatment with low doses of 
TMP-SMX may be needed.44 In AIDS patients, 
secondary treatment is maintained with low doses of 
TMP-SMX. Primary treatment is generally not needed 
in patients who are immunocompromised, because of 
the low incidence of nocardiosis.57 However, the 
extended use of TMP-SMX for the treatment of other 
opportunistic infections probably has a beneficial effect 
against nocardiosis.js Palacios et al7 reported 17 cases of 
nocardiosis in AIDS patients; only four of them were 
receiving treatment with TMP-SMX at the moment of 
diagnosis.7 
The clinical outcome of therapy depends on the site 
and extent of diseases and underlying host factors; cure 
rates of almost 100% are found in patients with skin and 
soft tissue involvement, as compared with 90% in 
pleuropulmonary disease, 60% in disseminated forms 
and 50% in brain abscesses. 44 Mortality is higher among 
immunocompromised patients and those with multiple 
brain abscesses. 
In summary, most of the patients have favorable 
outcomes and show good response to treatment, in 
almost all cases of immunosuppression, when early 
treatment is given.57,59 Delay in diagnosis and early 
suspension of treatment, especially in AIDS patients, is 
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